BioCentury
ARTICLE | Company News

Duchesnay, Alliance Pharma deal

September 19, 2016 7:00 AM UTC

The partners added Germany, France, Italy and six additional undisclosed EU countries to a 2015 deal granting Alliance rights to market Diclectin doxylamine/pyridoxine in the U.K. Alliance said it will pay L1 million ($1.3 million) for rights to the additional countries. Alliance submitted a regulatory application in the U.K. in 2Q15 for the delayed-release tablet containing 10 mg doxylamine and 10 mg pyridoxine for emesis in pregnant women and hopes to launch it in 2017. Duchesnay will supply the product to Alliance. ...